Martin J.S. Dyer
YOU?
Author Swipe
View article: The <scp>BH3</scp>‐only protein <scp>NOXA</scp> is essential for apoptosis induction by <scp>BH3</scp>‐mimetics targeting <scp>BCL2</scp> or <scp>BCL</scp>‐<scp>X<sub>L</sub></scp> in <scp>DLBCL</scp>
The <span>BH3</span>‐only protein <span>NOXA</span> is essential for apoptosis induction by <span>BH3</span>‐mimetics targeting <span>BCL2</span> or <span>BCL</span>‐<span>X<sub>L</sub></span> in <span>DLBCL</span> Open
Summary BCL2 inhibitors (BCL2i) have transformed the management of chronic lymphocytic leukaemia (CLL), but their use in more aggressive B‐cell malignancies such as diffuse large B‐Cell lymphoma (DLBCL) is complicated by the more heterogen…
View article: Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death
Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death Open
Despite the good options for the management of Diffuse large B‐cell lymphoma (DLBCL), a significant percentage of patients either do not respond to current treatments or relapse after a short time. Thus, a wider palette of targeted therape…
View article: In vitro comparison of <scp>CD20xCD3</scp> bispecific antibodies against diffuse large B‐cell lymphoma ( <scp>DLBCL</scp> ) cell lines with different levels of expression of <scp>CD20</scp>
In vitro comparison of <span>CD20xCD3</span> bispecific antibodies against diffuse large B‐cell lymphoma ( <span>DLBCL</span> ) cell lines with different levels of expression of <span>CD20</span> Open
Summary Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in diffuse large B‐cell lymphoma (DLBCL), some patients fail to respond and others relapse. To begin to explore possible limitations, we co…
View article: Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia Open
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the firs…
View article: Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia Open
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders and multiple sclerosis. Since the approval of the first…
View article: ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies
ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies Open
Introduction: Targeting the Mouse double minute 2 (MDM2)-p53 interaction, results in reactivation of wild-type (WT) TP53 and induction of transcriptional targets, causing cell death and cell cycle arrest. However, previous clinical studies…
View article: The chromosomal translocation <i>t</i> (1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to <i> <scp>RCC1</scp> :: <scp>IRF4</scp> </i> fusion
The chromosomal translocation <i>t</i> (1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to <i> <span>RCC1</span> :: <span>IRF4</span> </i> fusion Open
Summary The chromosomal translocation t (1;6)(p35.3;p25.2) is a rare but recurrent aberration in chronic lymphocytic leukaemia (CLL). We report molecular characterization of 10 cases and show that this translocation juxtaposes interferon r…
View article: Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma
Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma Open
To the Editor, Inhibitors of Bruton's tyrosine kinase (BTK) in chronic lymphocytic leukemia (CLL) result in durable responses in nearly all patients [1]. In contrast, in more aggressive B-cell malignancies, including diffuse large B cell l…
View article: Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia Open
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the firs…
View article: Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia Open
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders and multiple sclerosis. Since the approval of the first…
View article: Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia Open
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders and multiple sclerosis. Since the approval of the first…
View article: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study Open
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary ana…
View article: Data from Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis
Data from Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis Open
Chronic lymphocytic leukemia (CLL) is an incurable disease characterized by failure of mature lymphocytes to undergo apoptosis. CLL cells are inherently resistant to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). Pretreat…
View article: Supplementary Figure Legends from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells
Supplementary Figure Legends from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells Open
Supplementary figure legends
View article: Figure S1 from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells
Figure S1 from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells Open
Figure S1 shows protein expression of Hsp72, Hsc70, Nek6 and Nek7 in different cell types following different treatments.
View article: Figure S2 from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells
Figure S2 from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells Open
Figure S2 shows Hsp70 inhibition does not block clustering of acentrosomal spindle poles.
View article: Supplementary Figures 1-5 from Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis
Supplementary Figures 1-5 from Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis Open
Supplementary Figures 1-5 from Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis
View article: Data from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells
Data from Hsp72 and Nek6 Cooperate to Cluster Amplified Centrosomes in Cancer Cells Open
Cancer cells frequently possess extra amplified centrosomes clustered into two poles whose pseudo-bipolar spindles exhibit reduced fidelity of chromosome segregation and promote genetic instability. Inhibition of centrosome clustering trig…
View article: Supplemental Figure 4 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Supplemental Figure 4 from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia Open
Supplemental Figure 4. Free BTK levels at baseline and trough TIRA concentration for CLL patients treated with 80 mg TIRA
View article: Supplementary Figure S4 from CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL
Supplementary Figure S4 from CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL Open
Healthy B-cells are CXCL-8 negative.
View article: Supplementary Figure S2 from CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL
Supplementary Figure S2 from CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL Open
APRIL-producing neutrophils infiltrate the tumor nest.
View article: Supplementary Data from Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood
Supplementary Data from Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood Open
Supplementary Figure S1.